BMEA
Biomea Fusion, Inc.
Key Financials
Operating Income
$-83512000
↑ 42.0%
Revenue
$1.2B
N/A
EPS (Diluted)
$-1.18
↑ 69.2%
Total Assets
$58.6M
↓ 26.7%
Total Liabilities
$29.0M
↑ 2.3%
Net Income
$-61797000
↑ 55.4%
Shareholders' Equity
$29.6M
↓ 42.7%
Cash & Equivalents
$55.8M
↓ 4.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B5 | 9/22/2026 | View on SEC |
| 8-K | 9/22/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BMEA |
| Company Name | Biomea Fusion, Inc. |
| CIK | 1840439 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 980-9099 |